Search Results 651-660 of 18259 for Immunode

1. Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients - Mayo Clinic

   History of human immunodeficiency virus with acquired immunodeficiency syndrome at Screening. Active bacterial or fungal infection that is clinically ...

2. Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas - Mayo Clinic

   Known to be human immunodeficiency virus (HIV) positive. Known active hepatitis B or hepatitis C: Patients with a positive hepatitis B core antibody but ...

3. A Study of IPI-926 for Patients with Myelofibrosis - Mayo Clinic

   Known human immunodeficiency virus (HIV) positivity; Known hypersensitivity to IPI-926, or any of the excipients in IPI-926 capsules; Pregnant or lactating ...

4. A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Impaired Renal Function - Mayo Clinic

   Known human immunodeficiency virus infection. Presence of hepatitis B surface antigen (HbsAg) or hepatitis B core antibody (anti-HbcAb), at Screening or ...

5. A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies

   Human immunodeficiency virus (HIV) positive serology or AIDS; Active hepatitis B as defined by seropositivity for hepatitis B surface antigen or positive ...

6. Efficacy and Safety of Seralutinib in Adult Subjects With PAH - Mayo Clinic

   Human immunodeficiency virus (HIV)-associated PAH, schistosomiasis associated PAH, PAH associated with portal hypertension, or pulmonary veno-occlusive disease ...

7. A Study of an Implantable System for Remodulin Post Approval - Mayo Clinic

   Inclusion Criteria: Subject or legally authorized representative provides written authorization and/or consent per institution and geographical requirements ...

8. Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation - Mayo Clinic

   Subjects with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C. Subjects with any other medical or psychological condition ...

9. A Study to Evaluate CC-96191 to Treat Participants With Relapsed or Refractory Acute Myeloid Leukemia - Mayo Clinic

   Participant is known seropositive or active infection with human immunodeficiency virus (HIV), or active infection with hepatitis B virus or hepatitis C virus.

10. Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) - Mayo Clinic

    toxicity. 13. Participant has untreated, known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). In addition ...